Beseroldos

Quick links to important sections

Beseroldos

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beseroldos

Property Description
Active Ingredients Acetaminophen and Methocarbamol
Form Oral Solid Dosage Form (Tablet)
Pharmacological Class Non-opioid Analgesic and Centrally-acting Skeletal Muscle Relaxant
General Purpose Relief of acute painful musculoskeletal discomfort
Origin Synthetic Compound

Beseroldos is a synthetic fixed-dose combination (FDC) product provided as an oral solid dosage form, typically a tablet, which is clinically recognized for its dual mechanism in managing pain and muscle tension. It is classified pharmacologically as a combination of a non-opioid analgesic and a centrally-acting skeletal muscle relaxant (SMR). The FDC structure is a deliberate formulation strategy intended to provide simultaneous relief for conditions involving both pain and muscle tightness, differentiating it from single-ingredient preparations. This specific combination focuses on comprehensive relief for the adult patient population experiencing acute musculoskeletal distress.

The two active pharmaceutical ingredients in Beseroldos are Acetaminophen (Paracetamol) and Methocarbamol, which are both synthetic compounds. Methocarbamol, a carbamate derivative, is the component responsible for the muscle-relaxing effect, acting through the central nervous system. Methocarbamol is used for the reduction of muscle spasticity associated with various conditions. Acetaminophen is widely known for its ability to reduce the perception of pain (analgesia).

The overall purpose of Beseroldos is the general relief of discomfort associated with acute painful musculoskeletal conditions, such as back strains or minor injuries involving localized spasm. The combination provides a dual approach, leveraging the benefits of both muscle relaxation and pain mitigation simultaneously. This approach helps manage the cycle of muscle pain and tension that occurs during acute episodes.

What side effects are possible with Beseroldos?

Possible side effects and safety information

The official safety documents for Beseroldos (Acetaminophen and Methocarbamol) classify possible adverse reactions across several physiological systems. The most commonly reported effects involve the Nervous System and may include drowsiness, lightheadedness, dizziness, and nausea. These central nervous system (CNS) effects are noted in regulatory texts as potentially being more pronounced at the initiation of treatment.

Adverse reactions that are rarely documented include bradycardia, hypotension, syncope, and generalized allergic reactions involving the skin (e.g., rash, pruritus) or swelling (angioedema).

Serious Safety Considerations

Official labeling emphasizes the risk of Severe Hepatic Toxicity (liver damage) associated with the Acetaminophen component, a risk that is formally tied to long-term, high-dose exposure or acute overdose. For this reason, the medication is contraindicated in individuals with severe hepatic impairment. Other serious adverse reactions documented in regulatory documents include anaphylactic reactions, severe skin reactions (such as Stevens-Johnson syndrome), and blood dyscrasias.

Safety Restrictions and Context

Official prescribing information includes warnings regarding potential enhanced CNS depressant effects when Beseroldos is used concurrently with other CNS depressants, including alcohol. Additionally, the Methocarbamol component may cause color interference in certain laboratory tests, specifically screening tests for 5-HIAA and VMA, which is a key safety context noted in labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations of overdose for Beseroldos, a combination of Acetaminophen and Methocarbamol, and the required emergency actions as specified in government regulatory labeling.

Required Emergency Actions

Immediate medical advice must be sought in the event of any suspected overdose, even if the patient feels well or is asymptomatic, due to the potential for delayed, severe liver damage from the Acetaminophen component. Emergency services should be contacted immediately if severe symptoms, such as passing out or trouble breathing, are observed.

Documented Overdose Manifestations

Active Component Early Manifestations Severe Outcomes Antidote/Management
Acetaminophen Nausea, vomiting, pallor, anorexia, and abdominal pain. Acute liver failure, encephalopathy, cerebral edema, and death. N-acetylcysteine (NAC).
Methocarbamol Severe drowsiness, dizziness, and blurred vision. Seizures, coma, and hypotension. Symptomatic and supportive treatment.

Population-Specific Considerations

The risk of severe liver toxicity is officially documented as greater in certain populations, including those with chronic alcoholism, pre-existing hepatic impairment, chronic malnutrition, and in elderly individuals. Official management protocols require monitoring of vital signs, urinary output, and critical laboratory parameters to assess the extent of organ damage.

Therapeutic Uses of Beseroldos

What Beseroldos Treats: Main Uses and Benefits

Beseroldos is commonly used to help with symptomatic relief in situations involving certain distressing symptoms of the musculoskeletal system, where both pain and muscle spasm are present. The dual-action combination is applied across domains where additional symptomatic support is needed to address the co-occurrence of these manifestations.

This dual-action approach is relevant in contexts marked by increased discomfort or tension.

Dual Relief for Acute Muscular Pain and Spasm

The core therapeutic domain is the management of symptoms related to physical discomfort combined with symptoms of increased muscular activity and tension. The combination's approach provides supportive relief when symptoms related to physical discomfort and increased muscular activity occur together. This generally contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Supporting Acute Musculoskeletal Conditions

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is relevant for easing symptoms that interfere with daily functioning, such as acute low back pain (lumbago) or painful cervical muscle spasm. It is used in situations involving recurrent or episodic manifestations. Providing supportive relief when symptoms interfere with routine activities, Beseroldos supports the patient during difficult episodes by easing distress. It is commonly used when short-term symptomatic assistance is needed for managing localized discomfort and rigidity.


Quick Fact: Relief for Acute Localized Spasm

Eligibility and Restrictions for Use

Who can and cannot use Beseroldos?

The official eligibility profile for Beseroldos is defined by regulatory documents, specifying populations that are prohibited from use and groups where use is limited or requires conditional oversight.

Eligibility Status Defined Population Constraints
Contraindicated Use Use is strictly prohibited for patients with known hypersensitivity to Methocarbamol or Acetaminophen. It is also contraindicated in individuals with severe hepatic impairment or severe active liver disease due to the acetaminophen component.
Age-Related Restrictions Safety and effectiveness have not been established in patients under 16 years of age. The combination is indicated for adults and adolescents aged 16 and older. Older adults are considered a population requiring caution due to increased sensitivity to the muscle relaxant's effects.
Conditional Use & Caution Caution is warranted for patients with renal impairment, non-severe hepatic dysfunction, or a history of seizure disorder. The label advises caution when used in patients with Myasthenia Gravis who are taking anticholinesterase agents.
Reproductive Status The combination is not recommended for women who are or may become pregnant. Caution should be exercised when the medicine is administered to a woman who is breastfeeding.

What should I know about interactions with other medicines?

Beseroldos is officially documented to interact with several classes of medicinal products and substances, primarily due to the established properties of its two active components. All interaction statements are derived from official regulatory labeling.

Formal Regulatory Restrictions

The drug label strictly contraindicates co-administration with any other acetaminophen-containing product to prevent exceeding the recommended daily limit and to avoid the risk of severe liver damage. The use of Methocarbamol is also restricted in patients receiving Pyridostigmine Bromide due to the potential for the muscle relaxant to inhibit the anticholinesterase agent’s intended effect.

Pharmacodynamic and Metabolic Interactions

A primary interaction domain involves Central Nervous System (CNS) Depressants, including Opioids, Barbiturates, and Benzodiazepines. The co-administration of these agents may result in pharmacodynamic potentiation, leading to additive sedative effects. Furthermore, alcohol (ethanol) must be restricted, as its daily use significantly amplifies the risk of severe hepatotoxicity associated with the Acetaminophen component. Metabolism-based constraints apply to Enzyme Inducers such as Carbamazepine and Rifampin, which increase the formation of a toxic metabolite, thereby heightening the risk of liver injury.

Exposure and Special Constraints

Acetaminophen may alter the effect of Oral Anticoagulants like Warfarin, resulting in an increased International Normalized Ratio (INR). For agents such as Cholestyramine, which can reduce Acetaminophen absorption, a mandatory administration timing rule applies, requiring separation of doses by at least one hour. For populations with Hepatic or Renal Impairment, official documents note that Methocarbamol clearance is reduced, which may increase systemic exposure.

Mechanism of Action

Targeting the beta1 Adrenergic Receptors (The Cardiac Mechanism)

Beseroldos acts as a selective antagonist for the Beta-1 (beta1) adrenergic receptors found predominantly on the heart muscle and electrical conduction system. By competitively binding to these receptors, the drug physically blocks activation by natural catecholamines (stress hormones). This blockade initiates an intracellular cascade that dampens the Gs protein/cyclic AMP (cAMP) signaling pathway. The resulting decrease in both electrical signal frequency (chronotropy) and contractile force (inotropy) reduces the heart's mechanical work and its consumption of oxygen.


Modulation of the Renin-Angiotensin System (The Systemic Mechanism)

A secondary mechanistic action occurs in the kidneys, where Beseroldos blocks beta1 receptors on the juxtaglomerular cells. This specific antagonism limits the sympathetic drive that normally triggers the release of the enzyme renin. By reducing renin secretion, the drug interferes with the cascade that forms the vasoconstrictor Angiotensin II. Lowering Angiotensin II decreases systemic vascular resistance and alters the physiological regulation of fluid volume.

Dosage and Administration Information

Official Administration and Usage Guidelines

Beseroldos is a fixed-dose combination (FDC) medication administered through the oral route as a solid tablet, requiring intake with sufficient water. The proper use of this medicine is defined by specific dose limitations, scheduling, and duration constraints.


Standard Dosing and Frequency

The standard regimen for adults involves taking one to two tablets per dose, with the overall daily intake limited by specific product strengths to avoid exceeding the maximum daily dose for both active components. Administration is carried out in divided doses throughout the day, typically requiring dosing three or four times daily.

Patients are instructed to maintain a 4 to 6 hour interval between each dose. This structured approach to frequency and dosage is a core procedural requirement for its use.


Administration Specifics and Duration

Beseroldos is intended strictly for short-term use, with guidelines specifying that the treatment course should generally not exceed 30 days. The score line on the tablet, if present, is a practical feature intended for ease of swallowing only, and not for the division of the dose.

Population-specific adjustments are indicated: older adults may require a reduced dosage, and patients with hepatic impairment should have their dosing interval increased. Use is generally not recommended for children and adolescents due to insufficient data on safety and efficacy.

Recent Clinical Evidence

Research evidence / Overview of studies for Beseroldos


Research for Acute Painful Musculoskeletal Spasm

The evidence for Beseroldos was evaluated in research exploring how symptoms change over time in conditions associated with acute physical discomfort and spasm. Research methods included short-term Randomized Controlled Trials (RCTs), systematic reviews evaluating the entire class of centrally-acting skeletal muscle relaxants, and detailed regulatory analyses of scientific literature. The research was primarily conducted in adult patients experiencing conditions associated with limitations in movement or daily activity, such as acute low back pain. Studies examined outcomes related to physical discomfort by measuring key outcomes. Reports from short-term trials described various patterns observed in the studies regarding changes in pain severity scores. Regulatory bodies reviewed the available data and documented its applicability to short-term symptomatic use, consistent with the approved indication.


Evidence on Treatment Duration and Long-Term Outcomes

The evidence is derived from studies conducted during periods of increased symptom activity and applied in trials assessing short-term or episodic symptom patterns. The studies observing responses over defined time intervals were typically designed with follow-up periods only up to one week or eight days. Because follow-up durations were limited in these core studies, the regulatory assessments apply only to this acute, short-term research scenario. As a result, long-term effects are not well characterized, as the core research was not designed to evaluate extended periods of use. There is limited information for long-term outcomes or how symptoms evolve over several months.


Studies in Specific Patient Groups

The principal clinical research was evaluated in adult patients experiencing acute musculoskeletal symptoms. Research examined the adult populations studied, and data for certain groups of patients, such as older adults, remain insufficient or limited due to trial design. The study results reflect the specific conditions under which they were conducted and do not provide sufficient context for use in all patient groups, such as those with certain comorbidities.


Evidence Consistency and Areas Awaiting Further Research

While the available evidence describes patterns observed in short-term symptom research, the certainty remains low for some of the evidence evaluated in systematic reviews for the overall class of skeletal muscle relaxants. A key observation from regulatory reviews is the limited information available from recent, large-scale, high-quality Randomized Controlled Trials specifically on the fixed-dose combination. Additionally, comparative evidence is lacking regarding the patterns of outcomes between the fixed-dose combination and the use of the individual ingredients administered separately. The limitations mean that the evidence base carries documented inconsistencies and research gaps.

Frequently Asked Questions (FAQ)

Common questions about Beseroldos (FAQ)


Q: Are there specific food types that interact with Beseroldos?

Official regulatory documents explicitly warn against interactions with specific substances, most notably alcohol and certain medications. General food consumption is not listed as a restriction in the official product information.


Q: Can older adults typically use Beseroldos?

Regulatory documents state that use in older adults is described as requiring specific caution. This is because official research indicates one of the active components may stay in the system longer in this population. Therefore, a reduced dosage may be necessary, and monitoring may be advised.


Q: What is the typical time frame for staying on Beseroldos?

Beseroldos is intended for short-term symptomatic use for acute conditions only. Regulatory guidelines specify that the treatment duration is generally limited to a duration that does not exceed 30 days.


Q: Does Beseroldos cause long-term dependence?

Official product information notes that the Methocarbamol component is not designated as a controlled substance and is described as having a low risk of dependence. The drug is approved only for short-term use, consistent with its safety profile.


Q: Is Beseroldos available in a generic version?

Official documentation indicates that the active ingredients in Beseroldos, Acetaminophen and Methocarbamol, are common generic compounds. Consequently, the fixed-dose combination product is also available under various generic names.


Q: Is there a risk of withdrawal symptoms if Beseroldos is stopped suddenly?

Official sources state that withdrawal symptoms are uncommon with the Methocarbamol component. However, official documentation describes a gradual adjustment when stopping the medication to help avoid potential side effects that may occur from sudden cessation.


Q: What is the evidence regarding Beseroldos use during pregnancy?

The regulatory position is that the safety and potential for fetal harm from the Methocarbamol component are not established in humans. For this reason, official documents state that use is generally not recommended during pregnancy.


Q: How quickly does Beseroldos usually start to have an effect?

While specific onset timing is not listed on all regulatory labels, the pharmacological data provides context for the drug's action. The elimination half-life (the time it takes for half the drug to leave the system) of one active component is typically between 1 and 2 hours.


Q: Are there any common reasons why Beseroldos might be stopped?

Treatment with Beseroldos may be discontinued if a patient reaches the mandated maximum treatment duration, which is generally 30 days. Treatment may also be discontinued if a patient experiences serious or intolerable adverse reactions, such as excessive dizziness or the risk of liver issues noted in official warnings.


Q: What should I know about Beseroldos and driving or operating machinery?

Regulatory documents include a specific warning that Beseroldos may impair the mental and physical abilities required for operating machinery or driving a motor vehicle. This caution is due to the potential for side effects like dizziness or drowsiness.


Q: What happens if I miss a dose of Beseroldos?

Official guidelines address the procedure for a missed dose, noting the distinction between taking the dose upon recollection and skipping it if the next scheduled dose is imminent. The guidelines strictly prohibit taking a double dose to compensate for a missed one.


Q: What happens if I forget to tell my doctor I am taking Beseroldos when they prescribe me a new medicine?

Official documents include warnings that stress the importance of informing a healthcare provider of all medicines currently being taken, including over-the-counter products, before any new prescription. This warning is due to the documented risk of serious additive effects, particularly Central Nervous System (CNS) depression.


Q: Can Beseroldos be crushed or split?

Regulatory administration specifics note that the score line on the tablet, if present, is intended strictly for ease of swallowing. The score line is not intended for the division of the dose.


Q: Is it true that Beseroldos can affect sleep patterns?

Official safety documents list insomnia, or trouble sleeping, as one of the documented adverse reactions related to the nervous system.


Q: What is the difference between the active ingredient and the drug name?

The name 'Beseroldos' is the brand name of the medication used for marketing and identification. The 'active ingredients'—Acetaminophen and Methocarbamol—are the actual chemical compounds responsible for the drug’s pharmacological effects on the body.


Q: How does the time of day affect Beseroldos’s action?

The administration schedule is designed to maintain consistent levels of the active ingredients throughout the day. This requires taking the medicine in divided doses with a mandatory interval of 4 to 6 hours between each dose.


Q: What should I do if I am already taking several other medicines with Beseroldos?

Official guidance concerning Beseroldos includes warnings about its documented interactions with numerous substance classes. For this reason, regulatory documents stress the importance of providing a healthcare provider with a complete list of all medicines, including over-the-counter products.


Q: Can I use Beseroldos if I have a history of heart issues?

Regulatory documents define a mechanism of action for one component that includes effects on the beta1 adrenergic receptors in the heart, which reduces heart rate and contractile force. This component is associated with documented adverse reactions like bradycardia (slowed heart rate) and hypotension (low blood pressure).


How should Beseroldos be stored and disposed of?

Beseroldos (Acetaminophen/Methocarbamol tablets) must be stored and disposed of according to strict official regulatory guidelines to maintain product integrity and ensure safety.

Storage Requirements

Condition Regulatory Rule
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F) [DailyMed - NIH].
Protection Keep in the original container, tightly closed, away from excessive heat, moisture, and direct light [MedlinePlus - NIH].
Safety The product must be stored out of the reach and sight of children and pets [CDC].

Official Disposal Instructions

The preferred method for discarding unused or expired tablets is a drug take-back program (e.g., DEA-authorized collection sites) [US FDA]. If take-back options are unavailable, the medication can be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed container, and thrown into the household trash [US EPA]. The official labeling requires that you do not flush this medication down the toilet or drain [US EPA].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Beseroldos found in:

A-Z Index: